Cargando…

Plasma phosphorylated tau181 predicts cognitive and functional decline

OBJECTIVE: To determine if plasma tau phosphorylated at threonine 181 (p‐tau181) distinguishes pathology‐confirmed Alzheimer's disease (AD) from normal cognition (NC) adults, to test if p‐tau181 predicts cognitive and functional decline, and to validate findings in an external cohort. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tropea, Thomas F., Waligorska, Teresa, Xie, Sharon X., Nasrallah, Ilya M., Cousins, Katheryn A. Q., Trojanowski, John Q., Grossman, Murray, Irwin, David J., Weintraub, Daniel, Lee, Edward B., Wolk, David A., Chen‐Plotkin, Alice S., Shaw, Leslie M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852389/ https://www.ncbi.nlm.nih.gov/pubmed/36518085 http://dx.doi.org/10.1002/acn3.51695

Ejemplares similares

Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease
por: Cousins, Katheryn A. Q., et al.
Publicado: (2023)

Tau pathology associates with in vivo cortical thinning in Lewy body disorders
por: Spotorno, Nicola, et al.
Publicado: (2020)

Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting
por: Blömeke, Lara, et al.
Publicado: (2022)

Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease‐related declines
por: Thomas, Kelsey R., et al.
Publicado: (2021)

Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology
por: Sandelius, Åsa, et al.
Publicado: (2018)

Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau)
por: Gibbons, Garrett S., et al.
Publicado: (2019)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Self- and Partner-Reported Subjective Memory Complaints: Association with Objective Cognitive Impairment and Risk of Decline
por: Zuroff, Leah, et al.
Publicado: (2022)

Signature laminar distributions of pathology in frontotemporal lobar degeneration
por: Ohm, Daniel T., et al.
Publicado: (2022)

Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease
por: Lim, Nicholas S., et al.
Publicado: (2016)

Estimation of Tau and Phosphorylated Tau(181) in Serum of Alzheimer’s Disease and Mild Cognitive Impairment Patients
por: Shekhar, Shashank, et al.
Publicado: (2016)

Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases
por: Sheinerman, Kira S., et al.
Publicado: (2017)

Tau immunotherapy is associated with glial responses in FTLD-tau
por: Kim, Boram, et al.
Publicado: (2021)

Longitudinal naming and repetition relates to AD pathology and burden in autopsy‐confirmed primary progressive aphasia
por: Cousins, Katheryn A.Q., et al.
Publicado: (2021)

Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease
por: Irwin, David J., et al.
Publicado: (2013)

Longitudinal Changes in Semantic Concreteness in Semantic Variant Primary Progressive Aphasia (svPPA)
por: Cousins, Katheryn A. Q., et al.
Publicado: (2018)

Association of plasma P-tau181 with memory decline in non-demented adults
por: Therriault, Joseph, et al.
Publicado: (2021)

Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays
por: Blennow, Kaj, et al.
Publicado: (2019)

Tau-focused therapy and tau transmission: Implications for Alzheimer’s Disease and related tauopathies
por: Trojanowski, John Q
Publicado: (2013)

Apraxia of Speech in the Spontaneous Speech of Nonfluent/Agrammatic Primary Progressive Aphasia
por: Ash, Sharon, et al.
Publicado: (2023)

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer’s disease
por: Chen, Shi-Dong, et al.
Publicado: (2021)

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
por: Moscoso, Alexis, et al.
Publicado: (2020)

Phosphorylated Tau 181 Serum Levels Predict Alzheimer’s Disease in the Preclinical Stage
por: Qin, Wei, et al.
Publicado: (2022)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
por: Gangishetti, Umesh, et al.
Publicado: (2018)

Retina tissue validation of optical coherence tomography determined outer nuclear layer loss in FTLD-tau
por: Kim, Benjamin J., et al.
Publicado: (2021)

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
por: Thijssen, Elisabeth H., et al.
Publicado: (2020)

Phosphorylated tau/amyloid beta 1-42 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus
por: Patel, Sunil, et al.
Publicado: (2012)

Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients
por: Huang, Yanlu, et al.
Publicado: (2022)

Erratum to: Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
Publicado: (2021)

Correlation between cognitive impairment and serum phosphorylated tau181 protein in patients with preeclampsia
por: Wang, Yuanyuan, et al.
Publicado: (2023)

An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline
por: Trzeciakiewicz, Hanna, et al.
Publicado: (2020)

Decision-Making Deficits Associated with Amyloidosis in Lewy Body Disorders
por: Spotorno, Nicola, et al.
Publicado: (2017)

Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: a systematic review and meta-analysis
por: Ding, Xulong, et al.
Publicado: (2021)

Event-based modeling of T1-weighted MRI is related to pathology in frontotemporal lobar degeneration due to tau and TDP
por: Olm, Christopher A., et al.
Publicado: (2022)

Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau
por: McCollum, Lauren E., et al.
Publicado: (2021)

Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology
por: Portelius, Erik, et al.
Publicado: (2018)

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease
por: Moscoso, Alexis, et al.
Publicado: (2021)

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

Elevation of plasma phosphorylated tau181 during neurological illnesses affecting consciousness and kidney dysfunction
por: Thanapornsangsuth, Poosanu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8aaqab239r8uidganslkt12its